Hypertension
Conditions
Keywords
Hypertension
Brief summary
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
Interventions
Patients under daily life treatment receiving Kinzal according to local drug information.
DRUGTelmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
Patients under daily life treatment receiving Kinzalplus according to local drug information.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hypertensive patients seen by the physician requiring antihypertensive treatment
Exclusion criteria
* According to the local drug information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure | After 1-2 weeks, 1month, 3-4 months |
Secondary
| Measure | Time frame |
|---|---|
| Change in Mean heart rate (bpm) | Baseline and 3-4 month |
| Change in Mean Weight (kg) | Baseline and 3-4 month |
| Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose) | Baseline and 3-4 month |
| Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment | Baseline |
| Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician. | After 3-4 month |
Countries
Switzerland
Outcome results
None listed